Drug Database
CO

COVID-19 vaccine (ZF2001 / Zifivax / ZF 2001)

✓ Approved

Anhui Zhifei Longcom Biopharma · Recombinant Proteins · Recombinant Proteins

What is COVID-19 vaccine?

COVID-19 vaccine is a recombinant proteins developed by Anhui Zhifei Longcom Biopharma. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesZF2001, Zifivax, ZF 2001
CompanyAnhui Zhifei Longcom Biopharma
Drug ClassRecombinant Proteins, Vaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Anhui Zhifei Longcom Biopharma

Therapeutic Indications

COVID-19 vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsCOVID-19✓ Approved

Related Research Articles

PubMedNursing open2026-07-25

Opinions, Attitudes, and Hesitancy Concern the Vaccination for COVID-19 Among Students of 'Alexander Xhuvani' University, Elbasan.

Abazaj Erjona E, Koja Gjergji G, Shundi Lila L, Sulejmani Zahide Z et al.

We investigated the opinions, attitudes and hesitancy concerning the vaccine against the COVID-19 virus among students at the university. A descriptive cross-sectional study. This is a cross-sectional and descriptive survey conducted at a university from October to November 2021. Being at least 18 years old until 28, regardless of gender, being a student in one of the six programs at FTMS, and agreeing to participate in this investigation and to respond to our questionnaire were the inclusion criteria for this study. The outcome measures were the percentage of people agreeing to be vaccinated, opinions, attitudes, and factors and reasons linked with vaccination reluctance toward COVID-19. The SPSS software was used to examine the data. ANOVA, t-test, and χ2 were performed to evaluate descriptive statistics, while logistic regression was used to find acceptance-influencing variables. Two-tailed tests were run, and a p-value of less than 0.05 was deemed statistically significant. Overall, of 242 participants, 74% were female, with a significant difference from males with a p = 0.02. About 66.1% of students identified the benefits and efficacy of controlling the disease, while 33.9% were not up to date on their vaccinations and thought that vaccinations could cause problems in the future. Students who did not want to be vaccinated were 27.7%. The results of this detailed study show skepticism concerning the COVID-19- vaccine among students of the university, even though the rate of vaccination resulted in 60.74%. All findings suggest that public education on the efficacy and safety of the COVID-19 vaccine is important for the future widespread use of the vaccine. In this study, we involved the public contribution to understand their opinions, attitudes, and hesitancy concerning the vaccination for COVID-19.

PMID 42499257
Read full article →
PubMedIndian journal of clinical biochemistry : IJCB2026-07-25

Assessment of Neutralizing Antibodies Against COVID-19: The Impact of Vaccination in Western Rajasthan.

Choudhary Varsha V, Khatri P K PK, Khinvasara Palak P, Aseri G K GK et al.

The COVID-19 pandemic has been a major public health disaster, wreaking havoc on people's finances, physical health, and emotional well-being. However, many cases go undetected because they are asymptomatic. The purpose of the study is to identify neutralizing antibodies against COVID-19 in Western Rajasthan, India before and after three months of vaccination among the study participants. The study collected blood samples from unvaccinated individuals willing to participate at a vaccination center between September 2021 and December 2021. Those on immunosuppressants or already vaccinated with a COVID-19 dose were excluded. Blood group and neutralizing antibody levels were determined using standard protocols. Statistical analysis was conducted to assess correlations between demographic and clinical features with neutralizing antibody positivity. The study found a significant increase in neutralizing antibody levels after COVID-19 vaccination for both Covishield and Covaxin recipients, as well as those previously vaccinated with Bacillus Calmette-Guérin (BCG), highlighting the vaccines' effectiveness in boosting immunity. The results underscore the importance of COVID-19 vaccination in enhancing immune response in individuals with prior infection. Covishield produces higher vaccine-induced IgG antibodies than Covaxin. BCG-vaccinated individuals show higher COVID-19 neutralizing antibodies post-vaccination.

PMID 42500335
Read full article →
PubMedHospital pharmacy2026-07-25

Distribution and Characteristics of Vaccine Adverse Events: Analysis of Over 2 Million Individual Case Safety Reports.

Castellana Eleonora E, Chiappetta Maria Rachele MR

To describe the distribution and characteristics of adverse events following immunization (AEFI) using a large US pharmacovigilance database. A retrospective descriptive analysis of Individual Case Safety Reports (ICSRs) from the FDA AEMS database (January 2017-March 2026) was conducted. Reports were analyzed by vaccine type, adverse event terms, demographics, reporting year, and reporter category. A total of 2 169 603 ICSRs were identified, with 44.0% classified as serious. COVID-19 vaccines accounted for 78.4% of reports, reflecting mass vaccination campaigns. The most frequently reported events were headache (12.8%), pyrexia (11.8%), and fatigue (11.1%), predominantly non-serious and consistent with known reactogenicity profiles. Reporting peaked in 2021 (48.8%). Females accounted for 60.6% of reports. Non-COVID vaccines contributed substantially fewer reports. Most vaccine-associated adverse events were mild and expected. Findings support a favorable benefit-risk profile and highlight the importance of continuous pharmacovigilance systems for vaccine safety monitoring.

PMID 42500260
Read full article →
PubMedPediatric research2026-07-25

Immunogenicity and safety of BNT162b2 vaccine in patients with juvenile immune mediated inflammatory disease.

Gadelha Carolina S E CSE, Terreri Maria Teresa MT, N Burian Ana Paula AP, da Fraga Aline C M ACM et al.

COVID-19 vaccines have significantly reduced mortality and are safe for healthy children; however, research in pediatric populations with juvenile immune-mediated inflammatory diseases (IMIDs) is limited. The Brazilian multicenter longitudinal SAFER-Study evaluates immunogenicity and safety of the BNT162b2/Pfizer vaccine in IMID patients. The juvenile cohort enrolled patients aged 12-17 years between August and December 2021 and compared them with adults under 40 years from the adult cohort. Safety was assessed by monitoring post-vaccination adverse events (AEs), immunogenicity was measured by IgG antibodies against the SARS-CoV-2 spike receptor-binding domain and seroconversion rates. A total of 123 participants were included: 86 adolescents and 37 adult controls. In adolescents, local AEs were most frequent; no serious or life-threatening AEs occurred. Significant increases in IgG-S levels were observed after the two doses in both cohorts (p < 0.001). Seroconversion after the second dose reached 97% overall and 100% after the third dose. In juvenile SLE and JIA patients, vaccination did not significantly affect disease activity. The BNT162b2 vaccine was safe and immunogenic in adolescents with IMIDs, including those with high immunosuppression and comorbidities, showing similar responses to adults. These findings support vaccination in this vulnerable population and contribute to evidence-based recommendations. BNT162b2 COVID-19 vaccine demonstrated a favorable safety profile and immunogenicity in adolescents with juvenile immune-mediated inflammatory diseases (IMID), with responses comparable to those observed in adults. Real life data on this population remain limited, and further evidence regarding vaccine safety and immunogenicity is needed. This study represents the first multicenter, longitudinal registry of Brazilian adolescents with IMID receiving BNT162b2. Comprehensive data on the safety and immunogenicity of BNT162b2 in highly immunosuppressed adolescents with IMID and comorbidities are crucial to guide clinical decision-making, mitigate vaccine hesitancy, and enhance vaccination coverage within this vulnerable population.

PMID 42498827
Read full article →
PubMedAnnals of Ibadan postgraduate medicine2026-07-25

MENSTRUAL PATTERN CHANGES AMONG WOMEN DURING THE COVID-19 PANDEMIC IN IBADAN, A CROSS-SECTIONAL STUDY.

Akinlusi F M FM, Abdus-Salam R A RA, Bello Y Y, Idowu O C OC et al.

Coronavirus disease (COVID-19) is an infectious respiratory disease characterised by a spectrum of symptoms ranging from asymptomatic to severe. The COVID-19 pandemic and subsequent lockdowns were associated with varying degrees of stress among individuals. The hypothalamus-pituitary-ovarian axis, which regulates the menstrual cycle, may be significantly affected by stress. To investigate the effect of COVID-19 infection and pandemic lockdown on the menstrual pattern of women. A cross-sectional study of women exposed to COVID-19 was conducted using a questionnaire to collect data on socio-demographic characteristics, COVID-19 exposure, and menstrual patterns. Participants were categorised based on their COVID-19 test results. Analyses were conducted using STATA (StataCorp L.L.C.) version 15.0 and at a significance level of p < 0.05. Among the 218 respondents, only 93 (42.7%) had testing for COVID- 19. Among those who tested, only 36 (16.5% of all participants) tested positive for COVID-19 infection. Majority of respondents (80.7%) had regular menses before pandemic lockdown. About 1 in 5 (21.4%) respondents reported changes in menstrual pattern. The odds of experiencing changes in menstrual pattern was not significantly higher among women who tested positive for SARS-CoV2 (aOR = 1.71, 95% CI: 0.47 - 6.23). Extremes of reproductive age was associated with menstrual irregularities before the pandemic and changes in menstrual pattern during the lockdown. Irregularities in menstrual pattern remains common especially in the early and late reproductive years. Changes in menstrual pattern was common among respondents during the pandemic lockdown. Infection with SARS-CoV2 virus was not associated changes in menstrual pattern during the pandemic.

PMID 42499465
Read full article →
PubMedActa psychologica2026-07-25

COVID-19 servicescape and its consequences in the COVID-19 pandemic era.

Kim Sung-Hoon SH, Cho Byung-Kwan BK, Lee Yong-Ki YK, Yang Jae-Jang JJ

This study examines the COVID-19 servicescape of cafés and investigates how it affects enjoyment and COVID-19 anxiety, which in turn influence revisit intention. The proposed model is based on the two-factor theory and the cognition-affect-behavior model. Data were collected from online survey panel members and analyzed with SmartPLS 4.0.8. The findings show that, within the physical dimension, atmospherics, menu, and self-service technology positively influence enjoyment. Within the social dimension, uncrowdedness negatively affects enjoyment, whereas sanitary safety and employee service influence enjoyment and revisit intentions only indirectly through COVID-19 anxiety. Complementing these findings, Necessary Condition Analysis (NCA) identifies sanitary safety as a necessary condition for revisit intentions despite its nonsignificant direct effect. The study offers both theoretical and practical implications for servicescape management in the pandemic era.

PMID 42497617
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about COVID-19 vaccine